Catalio Capital Management

Catalio Capital Management is a venture capital firm founded in 2020 and based in New York, specializing in investments within the biomedical technology sector. The firm manages multiple funds, including the Catalio Access Funds and various special opportunities and credit funds. Catalio employs a diverse investment strategy that encompasses private equity, private credit, and public equity, utilizing a long bias and fundamental analysis approach. With a focus on breakthrough biomedical technologies, Catalio aims to support innovative companies in this rapidly evolving industry. Additionally, the firm is a Registered Investment Adviser, ensuring compliance with regulatory standards in its investment activities.

James Allison

Venture Partner

Jonathan Blankfein

Partner and Portfolio Manager

Thomas Brooks

Partner and Member of the Investment Committee

Tom V. Brooks

Partner

Prof. Joan S. Brugge

Venture Partner

Michael Cheaney

Vice President

Will Denehy

Vice President

Napoleone Ferrara

Venture Partner

Elliot Fishman

Venture Partner

Jeffrey M. Friedman

Venture Partner

Justin Hanes

Venture Partner

Matthew J. Hobson

Principal

John Henry Iucker

General Partner and Head of Credit

Elie Kobrin

Partner and Head of Equities

Titia de Lange Ph.D

Venture Partner

Olga Maltseva

Partner and Head of Operations

Scott O'Sullivan

Principal and Head of Trading

George Petrocheilos

Co-Founder and Managing Partner

Adam Riess Ph.D

Venture Partner

Isaac Ro

Partner

Isaac Ro

Partner

Gregg L. Semenza

Venture Partner

Ben Snedeker

Partner and Co-Head of Public Equities

Rob Snyder

Partner

Solomon Snyder

Venture Partner

Vicky Sostilio

Vice President

Thomas C. Südhof

Venture Partner

Kenan Turnacioglu

General Partner

Jacob Vogelstein

Co-Founder and Managing Partner

Diamantis Xylas

Partner and Co-Head of Investments

Elias Zerhouni

Venture Partner

Gordana Novakovic Ph.D

Venture Partner

Hai Yan Ph.D

Venture Partner

Gregg Semenza Ph.D

Venture Partner

Debora Marks Ph.D

Venture Partner

James Collins Ph.D

Venture Partner

Joan Brugge Ph.D

Venture Partner

Jeffrey Friedman Ph.D

Venture Partner

Padmanee Sharma Ph.D

Venture Partner

Past deals in Laser

RefleXion Medical

Venture Round in 2022
RefleXion Medical Inc. specializes in developing a biologically-guided radiotherapy system aimed at transforming cancer treatment. The company’s innovative technology allows tumors to continuously signal their location during therapy, facilitating the simultaneous treatment of multiple tumors, particularly in cases of metastasis. The RefleXion X1 machine is currently cleared for various forms of radiotherapy, including stereotactic body radiotherapy (SBRT) and intensity-modulated radiotherapy (IMRT). At the core of RefleXion's approach is the integration of positron-emission tomography (PET) imaging, which enables real-time tumor tracking and dose adaptation based on the biological characteristics of the tumors. This advancement in radiotherapy promises to enhance precision in cancer treatment, offering a potential paradigm shift in radiation oncology. RefleXion Medical, incorporated in 2009 and based in Hayward, California, has established strategic collaborations, including partnerships with Telix Pharmaceuticals and HealthMyne.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.